← Back to Clinical Trials
Recruiting NCT07603102

NCT07603102 Mindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07603102
Status Recruiting
Phase
Sponsor Nanjing Mingzhou Rehabilitation Hospital
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2026-05-01
Primary Completion 2026-11

Eligibility & Interventions

Sex All sexes
Min Age 55 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
mindfulnessDual-Task TrainingAerobic Training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2026-05-01 with a primary completion date of 2026-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to investigate whether a combined intervention of mindfulness and dual-task training can improve cognitive function and physical performance in individuals with mild cognitive impairment after stroke.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI). * Time since stroke onset ≥3 months and medically stable. * Presence of mild cognitive impairment after stroke, defined by a Montreal - - Montreal Cognitive Assessment (MoCA) score \< 26. * Mini-Mental State Examination (MMSE) score ≥ 24. * Ability to walk independently with or without an assistive device for at least 10 meters. * Stable medication regimen for at least 4 weeks prior to enrollment. * Ability to understand study instructions and provide written informed consent. Exclusion Criteria: * Severe aphasia, visual impairment, hearing impairment, or communication disorders that interfere with assessment or training participation. * Severe depression or other major psychiatric disorders. * Other neurological diseases affecting cognition or movement (e.g., Parkinson's disease, multiple sclerosis, traumatic brain injury). * Severe musculoskeletal, cardiovascular, or systemic diseases that contraindicate exercise participation. * Participation in other structured cognitive or rehabilitation intervention programs within the past 3 months. * Unstable medical condition or recurrent stroke during the study period. * Inability to safely complete the training protocol as determined by the study investigators.

Contact & Investigator

Central Contact

Jingzhi Zhang

✉ 170787717@qq.com

📞 +86-16677137704

Frequently Asked Questions

Who can join the NCT07603102 clinical trial?

This trial is open to participants of all sexes, aged 55 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07603102 currently recruiting?

Yes, NCT07603102 is actively recruiting participants. Contact the research team at 170787717@qq.com for enrollment information.

Where is the NCT07603102 trial being conducted?

This trial is being conducted at Nanjing, China.

Who is sponsoring the NCT07603102 clinical trial?

NCT07603102 is sponsored by Nanjing Mingzhou Rehabilitation Hospital. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology